Trial Profile
A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Fexofenadine; Quinidine
- Indications Allergic rhinitis; Arrhythmias; Deep vein thrombosis; Pulmonary embolism; Skin disorders; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record